Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Knee injection shows promise for regrowing cartilage in osteoarthritis

NCT ID NCT03275064

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental protein called LNA043, given as injections into the knee, to see if it can help regrow cartilage in people with knee osteoarthritis or cartilage injuries. 142 adults participated in two parts: one for cartilage lesions and one for osteoarthritis. The goal was to check safety and whether the treatment improves cartilage quality and volume on MRI scans.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LNA043 (a protein injection into the knee joint)
What this could lead to
If successful, this could point toward a treatment that helps regrow knee cartilage, potentially reducing pain and delaying the need for joint replacement.
What could go wrong
This is an early Phase 2 trial with only 142 participants, so results may not apply to everyone. The treatment involves multiple injections and may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

142 people

The number who actually took part.

Started

Sep 2017

Finished

Sep 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria Part A * Patient was ≥18 and ≤55 years old at time of screening. * Patient had a body mass index (BMI) \<30 kg/m2 at screening, * Patient had a symptomatic, single, articular cartilage defect of one knee, grade II or IIIA according to the ICRS classification, localized to either the femoral condyles/femoral trochlea or to the patella, based on MRI or arthroscopy performed within 9 months before screening visit and confirmed by screening 3T MRI. * Patient had an onset of pain and impairment of function between two (2) months and two (2) years before screening. * Patient had a grade 2 or 3 OA of the knee with Joint Space Width (JSW) 2-4 mm evaluated with X-Ray at screening Inclusion criteria Part B * Patient was ≥18 and ≤75 years old at time of screening. * Patient had a body mass index (BMI) ≤ 35 kg/m2 at screening * Diagnosis of femorotibial osteoarthritis (OA) in the target knee by standard American College of Rheumatology (ACR) criteria at study start (clinical AND radiographic criteria) * Patient must have had symptomatic disease predominantly in one (the index) knee, with minimal or no symptoms in the contralateral knee. Symptomatic disease is defined as having pain in the knee more than 50% of the days during the last 3 months from screening. * Patient had a K\&L grade 2 or 3 OA of the knee with JSW 2.00-4.00 mm (X=0.225) fixed position evaluated with X-Ray by the Central Reader at screening. Exclusion criteria Part A \& B * Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 15 days after stopping of investigational drug. * Patient had surgical treatment of the target knee using mosaicplasty, microfracture, meniscectomy \>50% (Note: prior diagnostic arthroscopy with debridement and lavage, \<50% meniscectomy, lateral release, patellar realignment, medial patellofemoral ligament reconstruction are acceptable if performed at least 2 months prior to screening; anteriorcruciate ligament reconstrucion is acceptable if performed 12 months prior to screening, or less if restoration of joint function is evident, and agreed by the sponsor). * Patient had an unstable target knee joint or insufficiently reconstructed ligaments based on medical history and physical examination by the investigator. * Prohibited medication updated with reference to dosing (formerly screening). Exclusion Criteria Part A only * Regular smokers (\> 5 cigarettes/day). Urine cotinine levels will be measured during screening for all patients. Regular smokers will be defined as any patient who reports tobacco use of \> 5 cigarettes/day and/or who has a urine cotinine ≥ 500 ng/mL. * Patient had radiologically apparent degenerative joint disease in the target knee as determined by Kellgren and Lawrence grade ≥2 based on X-ray evaluation performed within 9 months from screening. * Patient had patellofemoral dysplasia Dejour Grade B-D based on X-ray evaluation performed within 9 months from screening * Patient had malalignment (valgus- or varus-deformity) in the target knee ≥ 5° based on X-ray evaluation performed within 9 months from screening. In suspected cases, the mechanical axis must be established radiographically through complete leg imaging during standing and in postero-anterior (PA) projection. Exclusion Criteria Part B only * Regular smokers (\> 10 cigarettes/day). * Clinical signs of inflammation (i.e., redness) in the target knee. * History of knee replacement (unilateral or total) in either knee. * Presence of severe hip OA conditioning lower limb function according to PI's evaluation. * Nephrotic syndrome and/or significant proteinuria * History of coagulopathy or medical condition requiring anticoagulation which would preclude knee injection * Patient had malalignment (valgus- or varus-deformity) in the target knee ≥ 7.5° based on X-ray evaluation. In suspected cases, the mechanical axis must be established radiographically through complete leg imaging during standing and in postero-anterior (PA) projection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Articular cartilage lesion of the knee are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Arizona Research

    Phoenix, Arizona, 85053, United States

  • Clinical Research of West Florida Inc

    Tampa, Florida, 33606, United States

  • LV Research

    Las Vegas, Nevada, 89119, United States

  • Midwest Orthopedics At Rush

    Chicago, Illinois, 60612, United States

  • Northern California Research

    Sacramento, California, 95821, United States

  • Novartis Investigative Site

    Brno, Czech Republic, 66250, Czechia

  • Novartis Investigative Site

    Mladá Boleslav, Czech Republic, 29301, Czechia

  • Novartis Investigative Site

    Kladno, 272 59, Czechia

  • Novartis Investigative Site

    Kolín, 280 02, Czechia

  • Novartis Investigative Site

    Pardubice, 53002, Czechia

  • Novartis Investigative Site

    Prague, 190 00, Czechia

  • Novartis Investigative Site

    Aarhus N, 8200, Denmark

  • Novartis Investigative Site

    Hvidovre, 2650, Denmark

  • Panax Clinical Research

    Miami Lakes, Florida, 33014, United States

  • Precision Clinical Research LLC

    Sunrise, Florida, 33351, United States

  • Scott A Hacker MD Medical Group d b a Horizon Clinical Res

    La Mesa, California, 91942, United States

  • St Lukes Intermountain Research Center

    Boise, Idaho, 83702, United States

  • Sundance Clinical Research LLC

    St Louis, Missouri, 63141, United States

  • Temple University

    Philadelphia, Pennsylvania, 19140, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.